Proteomics International Laboratories (ASX:PIQ)
ASX announcement history & article coverage
Transparent by design.
Announcments by Proteomics International Laboratories (ASX:PIQ) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4E and Annual Report
Proteomics International reports FY2026 revenue growth, increased net loss, strategic reset, and new distribution deal
Appendix 4G and Corporate Governance Statement
Australian patent for PromarkerEndo
Proteomics International secures Australian patent acceptance for PromarkerEndo endometriosis diagnostic test
Change in substantial holding
Quarterly Activities/Appendix 4C Cash Flow Report
Proteomics International announces restructure, Healius distribution deal, US patent, and Q4 FY26 cash burn
Webinar Presentation - Healius distribution agreement
Proteomics signs national distribution deal with Healius
Proteomics International inks exclusive national distribution deal with Healius for Promarker® tests
Application for quotation of securities - PIQ
US patent secured for PromarkerEndo
Proteomics International secures US patent for PromarkerEndo endometriosis diagnostic test
Notification of cessation of securities - PIQ
Response to ASX Price Query
Proteomics International denies undisclosed info amid unusual trading, confirms ASX compliance
Change of Registered Office Address
Application for Quotation of Securities - PIQ